Soleno rises after $100 million share repurchase program

Soleno Therapeutics

11/11/2025 13:48

** Shares of drugmaker Soleno Therapeutics SLNO.O rise 8% to $50.05 premarket

** Soleno enters agreement with Jefferies LLC to repurchase $100 million of Soleno's common stock

** Co says it will make an initial payment of $100 million and receive about 1.5 million shares at first, based on Monday's closing price of $46.31/shr

** Final number of shares will be subject to adjustments related to the terms of the buyback deal

** "These actions demonstrate our confidence in our commercial launch and the compelling opportunity for VYKAT XR to become a foundational therapy for patients with hyperphagia associated with Prader Willi syndrome," says CEO Anish Bhatnagar

** The repurchase is expected to complete in Q1 2026

** 9 of 12 brokerages rate the stock "buy" or higher, and 3 at "hold"; their median PT is $112.50 – data compiled by LSEG

** Up to last close, stock up ~3% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))